Source: Frontiers in Immunology. Unidade: ICB
Subjects: IMUNOLOGIA, CÉLULAS SANGUÍNEAS, MEDULA ÓSSEA DE ANIMAL, CÉLULAS MIELOIDES, PARACOCCIDIOIDOMICOSE, DERMATOPATIAS INFECCIOSAS, FÁRMACOS IMUNOSSUPRESSORES, PULMÃO, INFECÇÕES RESPIRATÓRIAS
ABNT
PREITE, Nycolas Willian et al. Myeloid-derived suppressor cells are associated with impaired Th1 and Th17 responses and severe pulmonary paracoccidioidomycosis which is reversed by anti-Gr1 therapy. Frontiers in Immunology, v. 14, p. 1-19, 2023Tradução . . Disponível em: https://doi.org/10.3389/fimmu.2023.1039244. Acesso em: 17 nov. 2024.APA
Preite, N. W., Kaminski, V. de L., Borges, B. M., Calich, V. L. G., & Loures, F. V. (2023). Myeloid-derived suppressor cells are associated with impaired Th1 and Th17 responses and severe pulmonary paracoccidioidomycosis which is reversed by anti-Gr1 therapy. Frontiers in Immunology, 14, 1-19. doi:10.3389/fimmu.2023.1039244NLM
Preite NW, Kaminski V de L, Borges BM, Calich VLG, Loures FV. Myeloid-derived suppressor cells are associated with impaired Th1 and Th17 responses and severe pulmonary paracoccidioidomycosis which is reversed by anti-Gr1 therapy [Internet]. Frontiers in Immunology. 2023 ; 14 1-19.[citado 2024 nov. 17 ] Available from: https://doi.org/10.3389/fimmu.2023.1039244Vancouver
Preite NW, Kaminski V de L, Borges BM, Calich VLG, Loures FV. Myeloid-derived suppressor cells are associated with impaired Th1 and Th17 responses and severe pulmonary paracoccidioidomycosis which is reversed by anti-Gr1 therapy [Internet]. Frontiers in Immunology. 2023 ; 14 1-19.[citado 2024 nov. 17 ] Available from: https://doi.org/10.3389/fimmu.2023.1039244